Search Results - "Sutton, Rachel E"

Potently neutralizing and protective human antibodies against SARS-CoV-2 by Zost, Seth J., Gilchuk, Pavlo, Case, James Brett, Binshtein, Elad, Chen, Rita E., Nkolola, Joseph P., Schäfer, Alexandra, Reidy, Joseph X., Trivette, Andrew, Nargi, Rachel S., Sutton, Rachel E., Suryadevara, Naveenchandra, Martinez, David R., Williamson, Lauren E., Chen, Elaine C., Jones, Taylor, Day, Samuel, Myers, Luke, Hassan, Ahmed O., Kafai, Natasha M., Winkler, Emma S., Fox, Julie M., Shrihari, Swathi, Mueller, Benjamin K., Meiler, Jens, Chandrashekar, Abishek, Mercado, Noe B., Steinhardt, James J., Ren, Kuishu, Loo, Yueh-Ming, Kallewaard, Nicole L., McCune, Broc T., Keeler, Shamus P., Holtzman, Michael J., Barouch, Dan H., Gralinski, Lisa E., Baric, Ralph S., Thackray, Larissa B., Diamond, Michael S., Carnahan, Robert H., Crowe, James E.

“…The ongoing pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major threat…”
Get full text

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein by Suryadevara, Naveenchandra, Shrihari, Swathi, Gilchuk, Pavlo, VanBlargan, Laura A., Binshtein, Elad, Zost, Seth J., Nargi, Rachel S., Sutton, Rachel E., Winkler, Emma S., Chen, Elaine C., Fouch, Mallorie E., Davidson, Edgar, Doranz, Benjamin J., Chen, Rita E., Shi, Pei-Yong, Carnahan, Robert H., Thackray, Larissa B., Diamond, Michael S., Crowe, James E.

“…Most human monoclonal antibodies (mAbs) neutralizing SARS-CoV-2 recognize the spike (S) protein receptor-binding domain and block virus interactions with the…”
Get full text

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection by Winkler, Emma S., Gilchuk, Pavlo, Yu, Jinsheng, Bailey, Adam L., Chen, Rita E., Chong, Zhenlu, Zost, Seth J., Jang, Hyesun, Huang, Ying, Allen, James D., Case, James Brett, Sutton, Rachel E., Carnahan, Robert H., Darling, Tamarand L., Boon, Adrianus C.M., Mack, Matthias, Head, Richard D., Ross, Ted M., Crowe, James E., Diamond, Michael S.

“…SARS-CoV-2 has caused the global COVID-19 pandemic. Although passively delivered neutralizing antibodies against SARS-CoV-2 show promise in clinical trials,…”
Get full text

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein by Zost, Seth J., Gilchuk, Pavlo, Chen, Rita E., Case, James Brett, Reidy, Joseph X., Trivette, Andrew, Nargi, Rachel S., Sutton, Rachel E., Suryadevara, Naveenchandra, Chen, Elaine C., Binshtein, Elad, Shrihari, Swathi, Ostrowski, Mario, Chu, Helen Y., Didier, Jonathan E., MacRenaris, Keith W., Jones, Taylor, Day, Samuel, Myers, Luke, Eun-Hyung Lee, F., Nguyen, Doan C., Sanz, Ignacio, Martinez, David R., Rothlauf, Paul W., Bloyet, Louis-Marie, Whelan, Sean P. J., Baric, Ralph S., Thackray, Larissa B., Diamond, Michael S., Carnahan, Robert H., Crowe, James E.

“…Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce infection or disease during major epidemics. The novel…”
Get full text

Endothelial von Willebrand factor regulates angiogenesis by Starke, Richard D., Ferraro, Francesco, Paschalaki, Koralia E., Dryden, Nicola H., McKinnon, Thomas A.J., Sutton, Rachel E., Payne, Elspeth M., Haskard, Dorian O., Hughes, Alun D., Cutler, Daniel F., Laffan, Mike A., Randi, Anna M.

“…The regulation of blood vessel formation is of fundamental importance to many physiological processes, and angiogenesis is a major area for novel therapeutic…”
Get full text

Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals by Chen, Elaine C., Gilchuk, Pavlo, Zost, Seth J., Suryadevara, Naveenchandra, Winkler, Emma S., Cabel, Carly R., Binshtein, Elad, Chen, Rita E., Sutton, Rachel E., Rodriguez, Jessica, Day, Samuel, Myers, Luke, Trivette, Andrew, Williams, Jazmean K., Davidson, Edgar, Li, Shuaizhi, Doranz, Benjamin J., Campos, Samuel K., Carnahan, Robert H., Thorne, Curtis A., Diamond, Michael S., Crowe, James E.

“…Unrelated individuals can produce genetically similar clones of antibodies, known as public clonotypes, which have been seen in responses to different…”
Get full text

Broad and potently neutralizing monoclonal antibodies isolated from human survivors of New World hantavirus infection by Engdahl, Taylor B., Kuzmina, Natalia A., Ronk, Adam J., Mire, Chad E., Hyde, Matthew A., Kose, Nurgun, Josleyn, Matthew D., Sutton, Rachel E., Mehta, Apoorva, Wolters, Rachael M., Lloyd, Nicole M., Valdivieso, Francisca R., Ksiazek, Thomas G., Hooper, Jay W., Bukreyev, Alexander, Crowe, James E.

“…New World hantaviruses (NWHs) are endemic in North and South America and cause hantavirus cardiopulmonary syndrome (HCPS), with a case fatality rate of up to…”
Get full text

Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition by Kramer, Kevin J., Johnson, Nicole V., Shiakolas, Andrea R., Suryadevara, Naveenchandra, Periasamy, Sivakumar, Raju, Nagarajan, Williams, Jazmean K., Wrapp, Daniel, Zost, Seth J., Walker, Lauren M., Wall, Steven C., Holt, Clinton M., Hsieh, Ching-Lin, Sutton, Rachel E., Paulo, Ariana, Nargi, Rachel S., Davidson, Edgar, Doranz, Benjamin J., Crowe, James E., Bukreyev, Alexander, Carnahan, Robert H., McLellan, Jason S., Georgiev, Ivelin S.

“…The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineages that are more transmissible and resistant to currently approved antibody…”
Get full text

Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypes by Chen, Elaine C., Gilchuk, Pavlo, Zost, Seth J., Ilinykh, Philipp A., Binshtein, Elad, Huang, Kai, Myers, Luke, Bonissone, Stefano, Day, Samuel, Kona, Chandrahaas R., Trivette, Andrew, Reidy, Joseph X., Sutton, Rachel E., Gainza, Christopher, Diaz, Summer, Williams, Jazmean K., Selverian, Christopher N., Davidson, Edgar, Saphire, Erica Ollmann, Doranz, Benjamin J., Castellana, Natalie, Bukreyev, Alexander, Carnahan, Robert H., Crowe, James E.

“…Understanding the human antibody response to emerging viral pathogens is key to epidemic preparedness. As the size of the B cell response to a…”
Get full text

Isolation of a Potently Neutralizing and Protective Human Monoclonal Antibody Targeting Yellow Fever Virus by Doyle, Michael P, Genualdi, Joseph R, Bailey, Adam L, Kose, Nurgun, Gainza, Christopher, Rodriguez, Jessica, Reeder, Kristen M, Nelson, Christopher A, Jethva, Prashant N, Sutton, Rachel E, Bombardi, Robin G, Gross, Michael L, Julander, Justin G, Fremont, Daved H, Diamond, Michael S, Crowe, Jr, James E

“…Yellow fever virus (YFV) causes sporadic outbreaks of infection in South America and sub-Saharan Africa. While live-attenuated yellow fever virus vaccines…”
Get full text

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition by Greaney, Allison J., Starr, Tyler N., Gilchuk, Pavlo, Zost, Seth J., Binshtein, Elad, Loes, Andrea N., Hilton, Sarah K., Huddleston, John, Eguia, Rachel, Crawford, Katharine H.D., Dingens, Adam S., Nargi, Rachel S., Sutton, Rachel E., Suryadevara, Naveenchandra, Rothlauf, Paul W., Liu, Zhuoming, Whelan, Sean P.J., Carnahan, Robert H., Crowe, James E., Bloom, Jesse D.

“…Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being developed as therapeutics and are a major contributor to neutralizing…”
Get full text

Standardized two-step testing of antibody activity in COVID-19 convalescent plasma by Gilchuk, Pavlo, Thomsen, Isaac, Yoder, Sandra, Brady, Eric, Chappell, James D., Stevens, Laura J., Denison, Mark R., Sutton, Rachel E., Chen, Rita E., VanBlargan, Laura A., Suryadevara, Naveenchandra, Zost, Seth J., Schmitz, Jonathan, Pulley, Jill M., Diamond, Michael S., Rhoads, Jillian P., Bernard, Gordon R., Self, Wesley H., Rice, Todd W., Wheeler, Allison P., Crowe, James E., Carnahan, Robert H.

“…The COVID-19 pandemic revealed an urgent need for rapid profiling of neutralizing antibody responses and development of antibody therapeutics. The current Food…”
Get full text

Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail by Dong, Jinhui, Zost, Seth J., Greaney, Allison J., Starr, Tyler N., Dingens, Adam S., Chen, Elaine C., Chen, Rita E., Case, James Brett, Sutton, Rachel E., Gilchuk, Pavlo, Rodriguez, Jessica, Armstrong, Erica, Gainza, Christopher, Nargi, Rachel S., Binshtein, Elad, Xie, Xuping, Zhang, Xianwen, Shi, Pei-Yong, Logue, James, Weston, Stuart, McGrath, Marisa E., Frieman, Matthew B., Brady, Tyler, Tuffy, Kevin M., Bright, Helen, Loo, Yueh-Ming, McTamney, Patrick M., Esser, Mark T., Carnahan, Robert H., Diamond, Michael S., Bloom, Jesse D., Crowe, James E.

“…Understanding the molecular basis for immune recognition of SARS-CoV-2 spike glycoprotein antigenic sites will inform the development of improved therapeutics…”
Get full text

Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking by Shiakolas, Andrea R., Kramer, Kevin J., Johnson, Nicole V., Wall, Steven C., Suryadevara, Naveenchandra, Wrapp, Daniel, Periasamy, Sivakumar, Pilewski, Kelsey A., Raju, Nagarajan, Nargi, Rachel, Sutton, Rachel E., Walker, Lauren M., Setliff, Ian, Crowe, James E., Bukreyev, Alexander, Carnahan, Robert H., McLellan, Jason S., Georgiev, Ivelin S.

“…Although several monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been approved for coronavirus disease…”
Get full text

Pan-ebolavirus protective therapy by two multifunctional human antibodies by Gilchuk, Pavlo, Murin, Charles D., Cross, Robert W., Ilinykh, Philipp A., Huang, Kai, Kuzmina, Natalia, Borisevich, Viktoriya, Agans, Krystle N., Geisbert, Joan B., Zost, Seth J., Nargi, Rachel S., Sutton, Rachel E., Suryadevara, Naveenchandra, Bombardi, Robin G., Carnahan, Robert H., Bukreyev, Alexander, Geisbert, Thomas W., Ward, Andrew B., Crowe, James E.

“…Ebolaviruses cause a severe and often fatal illness with the potential for global spread. Monoclonal antibody-based treatments that have become available…”
Get full text

Human Antibodies Protect against Aerosolized Eastern Equine Encephalitis Virus Infection by Williamson, Lauren E., Gilliland, Theron, Yadav, Pramod K., Binshtein, Elad, Bombardi, Robin, Kose, Nurgun, Nargi, Rachel S., Sutton, Rachel E., Durie, Clarissa L., Armstrong, Erica, Carnahan, Robert H., Walker, Lauren M., Kim, Arthur S., Fox, Julie M., Diamond, Michael S., Ohi, Melanie D., Klimstra, William B., Crowe, James E.

“…Eastern equine encephalitis virus (EEEV) is one of the most virulent viruses endemic to North America. No licensed vaccines or antiviral therapeutics are…”
Get full text

Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface by Zost, Seth J, Dong, Jinhui, Gilchuk, Iuliia M, Gilchuk, Pavlo, Thornburg, Natalie J, Bangaru, Sandhya, Kose, Nurgun, Finn, Jessica A, Bombardi, Robin, Soto, Cinque, Chen, Elaine C, Nargi, Rachel S, Sutton, Rachel E, Irving, Ryan P, Suryadevara, Naveenchandra, Westover, Jonna B, Carnahan, Robert H, Turner, Hannah L, Li, Sheng, Ward, Andrew B, Crowe, Jr, James E

“…Broadly reactive antibodies targeting the influenza A virus hemagglutinin (HA) head domain are thought to be rare and to require extensive somatic mutations or…”
Get full text

Therapeutic alphavirus cross-reactive E1 human antibodies inhibit viral egress by Williamson, Lauren E., Reeder, Kristen M., Bailey, Kevin, Tran, Minh H., Roy, Vicky, Fouch, Mallorie E., Kose, Nurgun, Trivette, Andrew, Nargi, Rachel S., Winkler, Emma S., Kim, Arthur S., Gainza, Christopher, Rodriguez, Jessica, Armstrong, Erica, Sutton, Rachel E., Reidy, Joseph, Carnahan, Robert H., McDonald, W. Hayes, Schoeder, Clara T., Klimstra, William B., Davidson, Edgar, Doranz, Benjamin J., Alter, Galit, Meiler, Jens, Schey, Kevin L., Julander, Justin G., Diamond, Michael S., Crowe, James E.

“…Alphaviruses cause severe arthritogenic or encephalitic disease. The E1 structural glycoprotein is highly conserved in these viruses and mediates viral fusion…”
Get full text

Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions by Shiakolas, Andrea R., Kramer, Kevin J., Wrapp, Daniel, Richardson, Simone I., Schäfer, Alexandra, Wall, Steven, Wang, Nianshuang, Janowska, Katarzyna, Pilewski, Kelsey A., Venkat, Rohit, Parks, Robert, Manamela, Nelia P., Raju, Nagarajan, Fechter, Emilee Friedman, Holt, Clinton M., Suryadevara, Naveenchandra, Chen, Rita E., Martinez, David R., Nargi, Rachel S., Sutton, Rachel E., Ledgerwood, Julie E., Graham, Barney S., Diamond, Michael S., Haynes, Barton F., Acharya, Priyamvada, Carnahan, Robert H., Crowe, James E., Baric, Ralph S., Morris, Lynn, McLellan, Jason S., Georgiev, Ivelin S.

“…The continual emergence of novel coronaviruses (CoV), such as severe acute respiratory syndrome-(SARS)-CoV-2, highlights the critical need for broadly reactive…”
Get full text

Broad and potently neutralizing monoclonal antibodies isolated from human survivors of New World hantavirus infection by Engdahl, Taylor B., Kuzmina, Natalia A., Ronk, Adam J., Mire, Chad E., Hyde, Matthew A., Kose, Nurgun, Josleyn, Matthew D., Sutton, Rachel E., Mehta, Apoorva, Wolters, Rachael M., Lloyd, Nicole M., Valdivieso, Francisca R., Ksiazek, Thomas G., Hooper, Jay W., Bukreyev, Alexander, Crowe, James E.

Get full text